Germline mutations in 12 genes and risk of ovarian cancer in three population-based cohorts
Menée auprès de 1 509 témoins et 776 patientes atteintes d'un cancer épithélial de l'ovaire ou du péritoine, cette étude analyse l'association entre des mutations constitutionnelles de 12 gènes et le risque de développer la maladie
Background: With the widespread use of multigene panel genetic testing, population-based studies are necessary to accurately assess penetrance in unselected individuals. We evaluated the prevalence of germline pathogenic or likely pathogenic variants (mutations) in 12 cancer-predisposition genes and associations with ovarian cancer risk in three population-based prospective studies (Nurses’ Health Study [NHS], NHSII, Cancer Prevention Study II). Methods: We included women with epithelial ovarian or peritoneal cancer (n=776) and controls who were alive and had at least one intact ovary at the time of the matched case diagnosis (n=1,509). Germline DNA was sequenced for mutations in 12 genes. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for ovarian cancer risk by mutation status. Results: The mutation frequency across all 12 genes was 11.2% in cases and 3.3% in controls (P<0.0001). BRCA1 and BRCA2 were the most frequently mutated (3.5% and 3.8% of cases and 0.3% and 0.5% of controls, respectively) and were associated with increased ovarian cancer risk (OR, BRCA1=12.38; 95%CI=4.72-32.45; OR, BRCA2=9.18; 95%CI=3.98-21.15). Mutation frequencies for the other genes were ≤1.0% and only PALB2 was significantly associated with risk (OR=5.79; 95%CI=1.09-30.83). There was no difference in survival for women with a BRCA germline mutation versus no mutation. Conclusions: Further research is needed to better understand the role of other mutations in ovarian cancer among unselected populations. Impact: Our data support guidelines for germline genetic testing for BRCA1 and BRCA2 among women diagnosed with epithelial ovarian cancer; testing for PALB2 may be warranted.